XMU-MP-1
Based on 83 publication(s) in Google Scholar
XMU-MP-1 is a reversible and selective MST1/2 inhibitor with IC50s of 71.1 and 38.1 nM, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 2061980-01-4
- Formule: C17H16N6O3S2
- Masse moléculaire:416.48
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Peptidomimetic Library
HY-L033
-
Anti-Aging Compound Library
HY-L034
-
Targeted Diversity Library
HY-L099
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) XMU-MP-1
More- Nature. 2022 Jan;601(7894):600-605. [Abstract]
- Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
- Nat Immunol. 2017 Sep;18(9):973-984. [Abstract]
- Cancer Commun (Lond). 2023 May;43(5):582-612. [Abstract]
- Ann Rheum Dis. 2021 Jul;80(7):891-902. [Abstract]
- Nat Cell Biol. 2025 Jul;27(7):1148-1160. [Abstract]
- Nat Commun. 2022 Jun 2;13(1):3075. [Abstract]
- Autophagy. 2026 May;22(5):1021-1043. [Abstract]
- Theranostics. 2021 Jul 25;11(17):8480-8499. [Abstract]
- Sci Adv. 2024 Apr 12;10(15):eadm7600. [Abstract]
- J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
- Mater Today Bio. 2025 Oct 8:35:102394. [Abstract]
- Cell Death Dis. 2025 Dec 31. [Abstract]
- Cell Death Dis. 2025 Aug 11;16(1):608. [Abstract]
- Cell Death Dis. 2025 Jul 30;16(1):577. [Abstract]
- Cell Death Dis. 2025 May 28;16(1):422. [Abstract]
- Cell Death Dis. 2024 Jun 19;15(6):430. [Abstract]
- Cell Death Dis. 2021 Oct 5;12(10):907. [Abstract]
- Phytomedicine. 2026 Apr 26. [Abstract]
- EMBO J. 2025 Sep 1. [Abstract]
- Phytomedicine. 2025 May 21:143:156879. [Abstract]
- Phytomedicine. 2023 Jun:114:154761. [Abstract]
- EMBO J. 2023 Feb 15;42(4):e112184. [Abstract]
- Phytomedicine. 2020 Nov:78:153294. [Abstract]
- Apoptosis. 2024 May 17. [Abstract]
- Br J Pharmacol. 2019 Oct;176(20):3956-3971. [Abstract]
- Redox Rep. 2026 Dec;31(1):2643967. [Abstract]
- Oncogene. 2022 Feb;41(7):930-942. [Abstract]
- Aging Cell. 2021 Sep;20(9):e13465. [Abstract]
- Cell Death Discov. 2023 Oct 20;9(1):385. [Abstract]
- Cell Rep. 2025 Jul 26;44(8):116076. [Abstract]
- Cell Rep. 2021 Jul 13;36(2):109347. [Abstract]
- Cell Rep. 2017 Dec 19;21(12):3612-3623. [Abstract]
- Br J Cancer. 2025 Dec 13. [Abstract]
- Clin Transl Med. 2023 Mar;13(3):e1213. [Abstract]
- J Med Chem. 2022 Sep 8;65(17):11818-11839. [Abstract]
- Clin Transl Med. 2021 Sep;11(9):e478. [Abstract]
- Prog Neurobiol. 2025 Dec 11:257:102869. [Abstract]
- Food Funct. 2023 Nov 13;14(22):9999-10013. [Abstract]
- Inflamm Res. 2022 Aug;71(7-8):911-922. [Abstract]
- Stem Cell Reports. 2022 Mar 8;17(3):664-677. [Abstract]
- Int J Mol Sci. 2025 Apr 10;26(8):3576. [Abstract]
- Int Immunopharmacol. 2024 Jan 25:127:111443. [Abstract]
- Arthritis Res Ther. 2022 Nov 2;24(1):247. [Abstract]
- Biochem J. 2019 Mar 12;476(5):875-887. [Abstract]
- Poult Sci. 2026 Jan 13;105(3):106375. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2023 Jan 1;1869(1):166586. [Abstract]
- J Inflamm Res. 2025 Sep 10:18:12401-12419. [Abstract]
- iScience. 2024 Feb 16;27(3):109161. [Abstract]
- iScience. 2023 Jul 11;26(8):107293. [Abstract]
- J Biol Chem. 2026 Jun;302(6):113110. [Abstract]
- Cell Signal. 2020 Sep;73:109697. [Abstract]
- Development. 2025 Jun 16:dev.204483. [Abstract]
- Stem Cells. 2022 Mar 3;40(1):74-87. [Abstract]
- Exp Cell Res. 2023 Nov 15;432(2):113781. [Abstract]
- Exp Cell Res. 2022 Dec 15;421(2):113407. [Abstract]
- Clin Exp Hypertens. 2019;41(6):589-598. [Abstract]
- J Immunol. 2025 Mar 26:vkaf011. [Abstract]
- Thromb Res. 2023 Jan:221:83-91. [Abstract]
- Am J Physiol Renal Physiol. 2022 May 1;322(5):F512-F526. [Abstract]
- Pathol Res Pract. 2026 Jan:277:156299. [Abstract]
- Mol Carcinog. 2025 Aug;64(8):1330-1346. [Abstract]
- Environ Toxicol. 2020 Jun;35(6):643-651. [Abstract]
- Discov Oncol. 2025 Dec 23;17(1):163. [Abstract]
- Mol Biol Rep. 2026 Feb 13;53(1):384. [Abstract]
- Exp Physiol. 2020 Aug;105(8):1360-1372. [Abstract]
- SLAS Discov. 2024 Nov 5;29(8):100191. [Abstract]
- BMC Gastroenterol. 2025 May 8;25(1):342. [Abstract]
- Int J Endocrinol. 2025 Oct 13:2025:3385546. [Abstract]
- Biochem Biophys Res Commun. 2024 Jan 15:692:149323. [Abstract]
- Histochem Cell Biol. 2025 May 28;163(1):60. [Abstract]
- Lupus. 2023 Oct;32(12):1381-1393. [Abstract]
- Neurol Res. 2025 Nov 28:1-14. [Abstract]
- University of California. 2025.
- bioRxiv. 2025 Jul 18:2025.07.16.665213. [Abstract]
- Res Sq. 2025 May 29.
- University of Pittsburgh. 2025.
- bioRxiv. 2025 Apr 28:2024.04.18.590103. [Abstract]
- Research Square Preprint. 2024 Mar 19.
- bioRxiv. 2024 Jan 2.
- Research Square Preprint. 2023 Jun 1.
- Research Square Preprint. 2023 Apr 12.
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
WB
-
WB
-
Cell Imaging/Staining
-
IF
-
RT-PCR
Activité biologique
IC50: 71.1 (MST1), 38.1 nM (MST2)[1]
At concentrations ranging from 0.1 to 10 μM, XMU-MP-1 reduces the phosphorylation of endogenous MOB1, LATS1/2, and YAP in HepG2 cells in a dose-dependent manner. XMU-MP-1 treatment inhibits hydrogen peroxide-stimulated MOB1 phosphorylation and MST1/2 autophosphorylation in a variety of cell lines, including mouse macrophage-like cells, human osteosarcoma, human colorectal adenocarcinoma cells. XMU-MP-1 blocks MST1/2 kinase activities, thereby activating the downstream effector Yes-associated protein and promoting cell growth. XMU-MP-1 can potently and reversibly suppress the activities of kinases MST1/2 and enhance their downstream YAP activation in cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2061980-01-4
-
Appearance Solid
-
Masse moléculaire 416.48
-
Formule C17H16N6O3S2
-
Color Light yellow to yellow
-
SMILES
O=S(C1=CC=C(NC2=NC=C(C(N(C)C3=C4SC=C3)=N2)N(C)C4=O)C=C1)(N)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (83)
-
Journal Impact Factor
-
Most Recent
-
Nature
2022 Jan;601(7894):600-605. PMID: 34856602
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]
Left, representative phase-contrast images of trophospheres formed using 3 μM SC144 (top, 96 h) or 2 μM XMU-MP-1 (middle, 96 h), and aggregates of TSCs (bottom) deposited onto stimulated OFELs. Scale bar, 100 μm. Right, attachment efficiency. The results showed that the presence of XMU-MP-1 yielded trophospheres.
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jan;601(7894):600-605. [Abstract]
Immunofluorescence staining for NANOG (Yellow) and CDX2 (Cyan) (left), OCT4 (Yellow) and GATA3 (Cyan) (right) in representative trophospheres formed from a blastoid exposed to XMU-MP-1 (2 µM; 96 h). Scale bar: 50 μm
-
Cell Metab
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X. [Abstract]
Mouse CAFs were treated with HIPPO pathway inhibitor XMU-MP-1 (5 μM, 48h) and tested for HIPPO pathway proteins (YAP, phosphorylation YAP) and NNMT.
-
Nat Immunol
Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin. [Abstract]2017 Sep;18(9):973-984. PMID: 28671690
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2017 Sep;18(9):973-984. [Abstract]
Reduction of Spp1 expression by inhibiting MST1/2. BMMs were cultured on flat- or round-bottom plates (1×105 per well) with or without an Mst1/2 inhibitor (XMU-MP-1; 5 µg/mL).
-
Cancer Commun (Lond)
Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer. [Abstract]2023 May;43(5):582-612. PMID: 37005481
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2023 May;43(5):582-612. [Abstract]
Upper panel: WB analysis showing the effects of EGCG (50 µg/mL, 6 h) on expression of the autophagy markers LC3 and p62 in MCF7 and MDA-MB-231 cells with or without the MST1 kinase inhibitor XMU-MP-1 (8 µmol/L; 6 h). Lower panel: WB analysis showing the effects of EGCG (50 µg/mL, 6 h) on expression of the LC3 and p62 in MCF7 and MDA-MB-231 cells after YAP1 knockdown. The results showed that Inhibiting MST1 activity by treatment with XMU‐MP‐1 (8 µmol/L, 6 h) weakened the effects of EGCG on the autophagy markers LC3 II and p62, as did YAP1 knockdown.
-
Ann Rheum Dis
Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis. [Abstract]2021 Jul;80(7):891-902. PMID: 33858850 -
Nat Cell Biol
YAP maintains the dynamics of TDP-43 condensates and antagonizes TDP-43 pathological aggregates. [Abstract]2025 Jul;27(7):1148-1160. PMID: 40542195 -
Nat Commun
2022 Jun 2;13(1):3075. PMID: 35654829 -
Autophagy
Phase separation of OPTN initiates mitophagy to orchestrate craniofacial bone mineralization. [Abstract]2026 May;22(5):1021-1043. PMID: 41692957 -
Theranostics
Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-β signaling. [Abstract]2021 Jul 25;11(17):8480-8499. PMID: 34373754 -
Sci Adv
Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination. [Abstract]2024 Apr 12;10(15):eadm7600. PMID: 38608019 -
J Immunother Cancer
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. [Abstract]2024 Sep 6;12(9):e009327. PMID: 39244215 -
Mater Today Bio
Molybdenum disulfide induces growth inhibition and autophagy-dependent hepatocyte cell death through directly binding and regulating the activity of MST2. [Abstract]2025 Oct 8:35:102394. PMID: 41142426 -
Cell Death Dis
CRX is an intrinsic suppressor of epithelial‒mesenchymal transition in retinal pigment epithelial cells: a promising therapeutic avenue for subretinal fibrosis. [Abstract]2025 Dec 31. PMID: 41469516 -
Cell Death Dis
MCM7 promotes liver fibrosis by transcriptionally regulating IL11 via the SHCBP1-RACGAP1-STAT3 axis. [Abstract]2025 Aug 11;16(1):608. PMID: 40789837 -
Cell Death Dis
Astrocytic YAP prevents the glutamate neurotoxicity by upregulation of EAAT2 expression and promotes the gain of stemness in astrocytes in ischemic stroke mice. [Abstract]2025 Jul 30;16(1):577. PMID: 40739083 -
Cell Death Dis
2025 May 28;16(1):422. PMID: 40436845 -
Cell Death Dis
Hippo kinases Mst1 and Mst2 maintain NK cell homeostasis by orchestrating metabolic state and transcriptional activity. [Abstract]2024 Jun 19;15(6):430. PMID: 38898027 -
Cell Death Dis
Astrocytic YAP prevents the demyelination through promoting expression of cholesterol synthesis genes in experimental autoimmune encephalomyelitis. [Abstract]2021 Oct 5;12(10):907. PMID: 34611127 -
Phytomedicine
Rare ginsenoside Rk1 protects against cisplatin-induced auditory damage by regulating the MST1/LONP1 pathway. [Abstract]2026 Apr 26. PMID: 42097003 -
EMBO J
2025 Sep 1. PMID: 40890487 -
Phytomedicine
Curzerene suppresses epithelial-mesenchymal transition in gastric precancerous lesion cells through targeted regulation of YAP via the long non-coding RNA AFAP1-AS1. [Abstract]2025 May 21:143:156879. PMID: 40414046 -
Phytomedicine
The Ethyl acetate extract from Celastrus orbiculatus suppresses non-small-cell lung cancer by activating Hippo signaling and inhibiting YAP nuclear translocation. [Abstract]2023 Jun:114:154761. PMID: 37028249 -
EMBO J
2023 Feb 15;42(4):e112184. PMID: 36588499 -
Phytomedicine
Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling. [Abstract]2020 Nov:78:153294. PMID: 32771890 -
Apoptosis
MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer's Disease by modulating Hippo-Wnt signaling crosstalk. [Abstract]2024 May 17. PMID: 38760516 -
Br J Pharmacol
Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. [Abstract]2019 Oct;176(20):3956-3971. PMID: 31328787 -
Redox Rep
The hippo-YAP1/TEAD1-SLC7A5 axis: uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis. [Abstract]2026 Dec;31(1):2643967. PMID: 41833934 -
Oncogene
RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP. [Abstract]2022 Feb;41(7):930-942. PMID: 34615998 -
Aging Cell
YAP prevents premature senescence of astrocytes and cognitive decline of Alzheimer's disease through regulating CDK6 signaling. [Abstract]2021 Sep;20(9):e13465. PMID: 34415667 -
Cell Death Discov
YAP nuclear translocation induced by HIF-1α prevents DNA damage under hypoxic conditions. [Abstract]2023 Oct 20;9(1):385. PMID: 37863897 -
Cell Rep
The Hippo pathway kinase MST1 mediates a feedback loop to maintain NLRP3 inflammasome homeostasis. [Abstract]2025 Jul 26;44(8):116076. PMID: 40716062 -
Cell Rep
2021 Jul 13;36(2):109347. PMID: 34260916 -
Cell Rep
Homeostatic Control of Hpo/MST Kinase Activity through Autophosphorylation-Dependent Recruitment of the STRIPAK PP2A Phosphatase Complex. [Abstract]2017 Dec 19;21(12):3612-3623. PMID: 29262338
XMU-MP-1 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2017 Dec 19;21(12):3612-3623. [Abstract]
Control and SLMAP mutant HAP1 cells are probed for phosphorylation of MST1/2 (T183/180), YAP (S127 and S397) and MOB1 (T35). Note increased phosphorylation of these proteins in the SLMAP mutant cells, which is completely suppressed by XMU-MP-1 (10μM; 1 h).
-
Br J Cancer
Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer. [Abstract]2025 Dec 13. PMID: 41390896 -
Clin Transl Med
Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. [Abstract]2023 Mar;13(3):e1213. PMID: 36855786 -
J Med Chem
Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes. [Abstract]2022 Sep 8;65(17):11818-11839. PMID: 36037148 -
Clin Transl Med
Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. [Abstract]2021 Sep;11(9):e478. PMID: 34586722 -
Prog Neurobiol
The YAP/SCAP/SREBP1 pathway in astrocytes: A novel target for treating neonatal hypoxic-ischemic encephalopathy. [Abstract]2025 Dec 11:257:102869. PMID: 41390137 -
Food Funct
Oleanolic acid, a small-molecule natural product, inhibits ECM degeneration in osteoarthritis by regulating the Hippo/YAP and Wnt/β-catenin pathways. [Abstract]2023 Nov 13;14(22):9999-10013. PMID: 37856220 -
Inflamm Res
Inhibition of visfatin alleviates sepsis-induced intestinal damage by inhibiting Hippo signaling pathway. [Abstract]2022 Aug;71(7-8):911-922. PMID: 35731253 -
Stem Cell Reports
YAP signaling in horizontal basal cells promotes the regeneration of olfactory epithelium after injury. [Abstract]2022 Mar 8;17(3):664-677. PMID: 35148842 -
Int J Mol Sci
Knockdown of BAP31 Suppresses Tumorigenesis and Stemness in Breast Cancer Cells via the Hippo Pathway. [Abstract]2025 Apr 10;26(8):3576. PMID: 40332113 -
Int Immunopharmacol
Irisin mitigates rheumatoid arthritis by suppressing mitochondrial fission via inhibiting YAP-Drp1 signaling pathway. [Abstract]2024 Jan 25:127:111443. PMID: 38154212 -
Arthritis Res Ther
PSTPIP2 regulates synovial macrophages polarization and dynamics via ERβ in the joint microenvironment. [Abstract]2022 Nov 2;24(1):247. PMID: 36324152 -
Biochem J
Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2). [Abstract]2019 Mar 12;476(5):875-887. PMID: 30782972 -
Poult Sci
Novel insights into the regulation of NF2/SWH signaling in granulosa cells of prehierarchical follicle development in hen ovary. [Abstract]2026 Jan 13;105(3):106375. PMID: 41570527 -
Biochim Biophys Acta Mol Basis Dis
Inhibition of YAP by lenvatinib in endothelial cells increases blood pressure through ferroptosis. [Abstract]2023 Jan 1;1869(1):166586. PMID: 36374802 -
J Inflamm Res
Angiotensin-(1-7) Inhibits Angiogenesis and Alleviates Joint Damage in CIA Mice via the Hippo-YAP Pathway. [Abstract]2025 Sep 10:18:12401-12419. PMID: 40955298 -
iScience
2024 Feb 16;27(3):109161. PMID: 38444610 -
iScience
2023 Jul 11;26(8):107293. PMID: 37520709 -
J Biol Chem
Phosphatidylinositol 4-kinase α suppresses glioblastoma progression by inactivating YAP and PI3K/Akt signaling. [Abstract]2026 Jun;302(6):113110. PMID: 42103227 -
Cell Signal
Silence of lncRNA MIAT-mediated inhibition of DLG3 promoter methylation suppresses breast cancer progression via the Hippo signaling pathway. [Abstract]2020 Sep;73:109697. PMID: 32593652 -
Development
2025 Jun 16:dev.204483. PMID: 40521668 -
Stem Cells
2022 Mar 3;40(1):74-87. PMID: 35511870 -
Exp Cell Res
Dimethyl fumarate attenuates cholestatic liver injury by activating the NRF2 and FXR pathways and suppressing NLRP3/GSDMD signaling in mice. [Abstract]2023 Nov 15;432(2):113781. PMID: 37722551 -
Exp Cell Res
Vaspin alleviates the lncRNA LEF1-AS1-induced osteogenic differentiation of vascular smooth muscle cells via the Hippo/YAP signaling pathway. [Abstract]2022 Dec 15;421(2):113407. PMID: 36334793 -
Clin Exp Hypertens
Angiotensin-converting enzyme 2 activation suppresses pulmonary vascular remodeling by inducing apoptosis through the Hippo signaling pathway in rats with pulmonary arterial hypertension. [Abstract]2019;41(6):589-598. PMID: 30806090 -
J Immunol
Hippo-YAP pathway regulates antimicrobial immune response in obscure puffer Takifugu obscurus. [Abstract]2025 Mar 26:vkaf011. PMID: 40139813 -
Thromb Res
Mammalian STE20-like kinase-1/2 are activated in human platelets stimulated by collagen or thrombin and play a vital role in collagen-activated platelets. [Abstract]2023 Jan:221:83-91. PMID: 36495715 -
Am J Physiol Renal Physiol
MST1/2 in PDGFRα+ cells negatively regulates TGF-β-induced myofibroblast accumulation in renal fibrosis. [Abstract]2022 May 1;322(5):F512-F526. PMID: 35253468 -
Pathol Res Pract
EBF3 transcriptionally activates ACADL to block the Hippo/YAP signaling pathway and inhibits breast cancer progression. [Abstract]2026 Jan:277:156299. PMID: 41270467 -
Mol Carcinog
Downregulation of HTRA1 Promotes EMT and Anoikis Resistance in Colorectal Cancer via Activation of Hippo/YAP1 Pathway by Facilitating LATS2 Degradation. [Abstract]2025 Aug;64(8):1330-1346. PMID: 40418093 -
Environ Toxicol
Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells. [Abstract]2020 Jun;35(6):643-651. PMID: 31916386 -
Discov Oncol
Uncovering GSTK1 and PTGER3 as biomarkers for breast cancer prognosis through comprehensive analyses. [Abstract]2025 Dec 23;17(1):163. PMID: 41432840 -
Mol Biol Rep
Xmu-mp-1 attenuates streptozotocin-induced neurotoxicity in SH-SY5Y cells: potential role of Hippo pathway modulation. [Abstract]2026 Feb 13;53(1):384. PMID: 41686328 -
Exp Physiol
MicroRNA-188 inhibits biological activity of lung cancer stem cells through targeting MDK and mediating the Hippo pathway. [Abstract]2020 Aug;105(8):1360-1372. PMID: 32592428 -
SLAS Discov
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. [Abstract]2024 Nov 5;29(8):100191. PMID: 39510350 -
BMC Gastroenterol
Identification of the "Collagen-Macrophage" sub-category of patients with colorectal cancer as an extension of the CMS4 subtype with THBS2 as a therapeutic target. [Abstract]2025 May 8;25(1):342. PMID: 40340827 -
Int J Endocrinol
Neu-P11 Improves Type 2 Diabetes Mellitus Immune Function by Inhibiting the Hippo Signaling Pathway. [Abstract]2025 Oct 13:2025:3385546. PMID: 41122104 -
Biochem Biophys Res Commun
Activation of TAZ by XMU-MP-1 inhibits osteoclastogenesis and attenuates ovariectomy-induced cancellous bone loss. [Abstract]2024 Jan 15:692:149323. PMID: 38043154 -
Histochem Cell Biol
MST1 modulates inflammatory responses by targeting the NF-κB/NLRP3 pathway in LPS-induced acute lung injury. [Abstract]2025 May 28;163(1):60. PMID: 40434446 -
Lupus
FKN secreted by kidney epithelial cells regulates macrophage activation in lupus nephritis via the Hippo signaling pathway. [Abstract]2023 Oct;32(12):1381-1393. PMID: 37751892 -
Neurol Res
Melatonin regulates the MST1/Nrf2 pathway to alleviate oxidative stress injury after hypoxic-ischemic brain damage in neonatal rats. [Abstract]2025 Nov 28:1-14. PMID: 41312691 -
-
bioRxiv
Sustained Yap/Taz activation promotes aberrant alveolar epithelial cell differentiation and drives persistent fibrotic remodeling. [Abstract]2025 Jul 18:2025.07.16.665213. PMID: 40791334 -
-
-
bioRxiv
2025 Apr 28:2024.04.18.590103. PMID: 38659924 -
-
-
-
-
Solvant et solubilité
DMSO : 8 mg/mL (19.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.83 mg/mL (1.99 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.83 mg/mL (1.99 mM); Clear solution
This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
XMU-MP-1 is dissolved in DMSO (stock concentration, 10 mM). For the in vitro kinase inhibition assays, recombinant GST-tagged MOB1a and various forms of recombinant His-tagged full-length MST1 or MST2 kinase are expressed and purified from Escherichia coli. The assays are performed with the various doses of XMU-MP-1 in the kinase assay buffer for 30 min at 30°C[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4011 mL | 12.0054 mL | 24.0108 mL | 60.0269 mL |
| 5 mM | 0.4802 mL | 2.4011 mL | 4.8022 mL | 12.0054 mL | |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.4011 mL | 6.0027 mL | |
| 15 mM | 0.1601 mL | 0.8004 mL | 1.6007 mL | 4.0018 mL |
XMU-MP-1 Related Classifications
HY-100526 Related Classifications
Powered by Bioz